SCHEMBL7250295

SCHEMBL7250295

O=c1[nH]cnc(-c2ccncc2)c1-c1ccc(F)cc1

nearest known ligand 0.63

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 14/20 0.63
MAPK13 O15264 2/20 0.63
MAPK9 P45984 2/20 0.63
MAPK12 P53778 2/20 0.63
MAPK11 Q15759 2/20 0.63
RAF1 P04049 1/20 0.63
PDPK1 O15530 2/20 0.46
RAB9A P51151 1/20 0.46
MAPK10 P53779 1/20 0.44
PRKD3 O94806 1/20 0.43
MAP4K4 O95819 1/20 0.43
FRK P42685 1/20 0.43
GCGR P47871 1/20 0.43
CSNK1A1 P48729 1/20 0.43
CSNK1D P48730 1/20 0.43
GSK3B P49841 1/20 0.43
PTK6 Q13882 1/20 0.43
PRKD2 Q9BZL6 1/20 0.43
CLK4 Q9HAZ1 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6423292 0.78 MAPK14 (1.00) MAPK14MAPK13MAPK9MAPK12MAPK11
SCHEMBL4434902 0.78 MAPK14 (1.00) MAPK14MAPK13MAPK9MAPK12MAPK11
SCHEMBL6934304 0.75 MAPK14 (0.55) MAPK14MAPK13MAPK9MAPK12MAPK11
SCHEMBL6933891 0.75 MAPK14 (0.64) MAPK14MAPK13MAPK9MAPK12MAPK11
SCHEMBL8326530 0.74 MAPK14 (0.63) MAPK14RAB9ACSNK1D
SCHEMBL13946368 0.74 MAPK14 (0.49) MAPK14MAPK13MAPK9MAPK12MAPK11
SCHEMBL17016669 0.74 PDPK1 (0.55) MAPK14MAPK13MAPK9MAPK12MAPK11
SCHEMBL15577520 0.74 POLB (0.49) MAPK14MAPK13MAPK9MAPK12MAPK11
SCHEMBL14064490 0.74 MAPK14 (0.52) MAPK14MAPK13MAPK9MAPK12MAPK11
SCHEMBL7071770 0.74 XDH (0.61) MAPK14MAPK13MAPK9MAPK12MAPK11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1328277-C Substituted pyrimidinone and pyridinone compounds and their use AMGEN INC (US) 2007-07-25 CN disclosed
US-20030069425-A1 Substituted pyrimidine compounds and methods of use AMGEN INC. 2003-04-10 US disclosed
US-6420385-B1 INFLAMMATORY, PAIN AND DIABETES DISEASES, AMGEN INC. 2002-07-16 US disclosed
CN-1246857-A Substituted pyrimidinone and pyridinone compounds and their use AMGEN INC (US) 2000-03-08 CN disclosed
CN-1246858-A Substituted pyrimidine compounds and their use AMGEN INC (US) 2000-03-08 CN disclosed
EP-0948496-A2 SUBSTITUTED PYRIMIDINONE AND PYRIDONE COMPOUNDS AND METHODS OF USE Amgen inc. (US) 1999-10-13 EP disclosed
EP-0948497-A2 SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE Amgen inc. (US) 1999-10-13 EP disclosed
WO-1998024780-A2 SUBSTITUTED PYRIMIDINONE AND PYRIDINONE COMPOUNDS AND THEIR USE AMGEN INC. (US) 1998-06-11 WO disclosed
WO-1998024782-A2 SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE AMGEN INC. (US) 1998-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069425-A1 Substituted pyrimidine compounds and methods of use DPYD, IL6, IL1B MAPK14 2062/4885MAPK13 2250/4885MAPK9 1576/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.